MX2022001817A - Metodos para detectar isoformas de la region de union a microtubulos (mtbr) tau y uso de las mismas. - Google Patents

Metodos para detectar isoformas de la region de union a microtubulos (mtbr) tau y uso de las mismas.

Info

Publication number
MX2022001817A
MX2022001817A MX2022001817A MX2022001817A MX2022001817A MX 2022001817 A MX2022001817 A MX 2022001817A MX 2022001817 A MX2022001817 A MX 2022001817A MX 2022001817 A MX2022001817 A MX 2022001817A MX 2022001817 A MX2022001817 A MX 2022001817A
Authority
MX
Mexico
Prior art keywords
mtbr
tau species
detect
methods
blood
Prior art date
Application number
MX2022001817A
Other languages
English (en)
Inventor
Nicolas Barthelemy
Randall Bateman
Kanta Horie
Chihiro Sato
Original Assignee
Washington University St Louis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University St Louis filed Critical Washington University St Louis
Publication of MX2022001817A publication Critical patent/MX2022001817A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/34—Purifying; Cleaning
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

Los métodos descritos en la presente emplean combinaciones únicas de pasos de procesamiento que transforman una muestra de sangre o CSF en una muestra adecuada para cuantificar especies de MTBR tau, así como otras especies de tau. La presente descripción también abarca el uso de especies de MTBR tau en sangre o CSF para medir características patológicas y/o síntomas clínicos de tauopatías de 3R y 4R a fin de diagnosticar, graduar, y/o elegir tratamientos apropiados para una etapa de enfermedad determinada, y modificar un régimen de tratamiento determinado.
MX2022001817A 2019-08-13 2020-08-13 Metodos para detectar isoformas de la region de union a microtubulos (mtbr) tau y uso de las mismas. MX2022001817A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962886165P 2019-08-13 2019-08-13
US202062970950P 2020-02-06 2020-02-06
US202063044836P 2020-06-26 2020-06-26
PCT/US2020/046224 WO2021030615A1 (en) 2019-08-13 2020-08-13 Methods to detect mtbr tau isoforms and use thereof

Publications (1)

Publication Number Publication Date
MX2022001817A true MX2022001817A (es) 2022-03-11

Family

ID=74570452

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001817A MX2022001817A (es) 2019-08-13 2020-08-13 Metodos para detectar isoformas de la region de union a microtubulos (mtbr) tau y uso de las mismas.

Country Status (10)

Country Link
US (1) US20220299527A1 (es)
EP (1) EP4013772A4 (es)
JP (1) JP2022544514A (es)
KR (1) KR20220062287A (es)
CN (1) CN114555631A (es)
AU (1) AU2020331020A1 (es)
CA (1) CA3147548A1 (es)
IL (1) IL290492A (es)
MX (1) MX2022001817A (es)
WO (1) WO2021030615A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4096694A4 (en) 2020-01-30 2024-01-24 Prognomiq Inc LUNG BIOMARKERS AND METHODS OF USE THEREOF
WO2022212756A1 (en) * 2021-03-31 2022-10-06 Washington University Csf phosphorylated tau and amyloid beta profiles as biomarkers of tauopathies
CA3231038A1 (en) * 2021-09-13 2023-03-16 Bruce Wilcox Enhanced detection and quantitation of biomolecules
WO2023220276A1 (en) * 2022-05-11 2023-11-16 Washington University METHODS TO DETECT Aβ PROTEOFORMS AND USE THEREOF
WO2024107745A1 (en) * 2022-11-14 2024-05-23 Washington University Methods to detect csf mtbr-tau and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9518101B2 (en) * 2011-09-19 2016-12-13 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
US20150337030A1 (en) * 2012-05-31 2015-11-26 The Trustees Of Columbia University In The City Of New York Methods to treat alzheimer's disease using apoe inhibitors
KR20150036346A (ko) * 2012-07-03 2015-04-07 워싱턴 유니버시티 Tau에 대한 항체
WO2014011972A1 (en) * 2012-07-13 2014-01-16 Bristol-Myers Squibb Company Tau immunoassay
US20150253341A1 (en) * 2014-02-10 2015-09-10 Merck Sharp & Dohme Corp. Quantification of tau in biological samples by immunoaffinity enrichment and mass spectrometry
US10830775B2 (en) * 2014-09-30 2020-11-10 Washington University Tau kinetic measurements
EA037092B1 (ru) * 2015-07-06 2021-02-04 Юсб Биофарма Срл Тау-связывающие антитела
WO2018148593A1 (en) * 2017-02-10 2018-08-16 C2N Diagnostics, Llc Methods for measuring concentrations of biomolecules in biofluids
BR112020021782A2 (pt) * 2018-05-03 2021-02-23 Washington University métodos de diagnóstico e tratamento com base em fosforilação de tau específica de sítio

Also Published As

Publication number Publication date
US20220299527A1 (en) 2022-09-22
EP4013772A4 (en) 2024-06-05
AU2020331020A1 (en) 2022-03-03
KR20220062287A (ko) 2022-05-16
JP2022544514A (ja) 2022-10-19
CA3147548A1 (en) 2021-02-18
EP4013772A1 (en) 2022-06-22
CN114555631A (zh) 2022-05-27
WO2021030615A1 (en) 2021-02-18
IL290492A (en) 2022-04-01

Similar Documents

Publication Publication Date Title
MX2022001817A (es) Metodos para detectar isoformas de la region de union a microtubulos (mtbr) tau y uso de las mismas.
Chuang et al. Migraine and risk of dementia: a nationwide retrospective cohort study
MX2018008421A (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
GB2463401B (en) Characterizing prostate disorders by analysis of microvesicles
WO2015153864A3 (en) Methods for treating inflammatory conditions
Degerman Gunnarsson et al. High tau levels in cerebrospinal fluid predict rapid decline and increased dementia mortality in Alzheimer's disease
FR3060755B1 (fr) Methode de diagnostic d'une peau presentant des signes de secheresse
Rosén et al. Cerebrospinal fluid biomarkers in cardiac arrest survivors
NZ729773A (en) Biomarkers for disease progression in melanoma
WO2018026969A3 (en) Plazomicin antibodies and methods of use
CA2991055A1 (en) Diagnostic test for alzheimer's disease based on identification of a proteolytic pathway
WO2014197460A8 (en) Methods for diagnosing and treating bicuspid aortic valve and/or aortopathies
GB2569932A (en) Identification and use of very long chain dicarboxylic acids for disease diagnosis, chemoprevention, and treatment
BR112022003686A2 (pt) Tratamento de sintomas induzidos pelo ciclo menstrual
WO2020178447A8 (en) Method for determining efficacy
BR112014007947A2 (pt) método para monitoramento, diagnóstico e/ou prognóstico de distúrbios relacionados à hipoxia usando nfat5
MY179665A (en) In vitro diagnostic method for alzhemer's disease based on the albumin redox level in the cerebrospinal fluid
MX2023008614A (es) Metodos para detectar especies de csf tau con estado y progresion de la enfermedad de alzheimer, y uso de los mismos.
Nguyen et al. 22: Kidney knowledge survey: A validation study in Vietnamese language
WO2010093214A3 (en) Monoclonal antibody recognizing scye1 and use thereof
RU2014128849A (ru) Способ диагностики гастроэзофагельной рефлюксной болезни у детей
권병욱 et al. Association between Serum Vitamin D Level and Albuminuria in Korean Adults: Data from 2013 Korean National Health and Nutrition Examination Survey
Hendrickson et al. A42 ARDS: RISK, TREATMENT, AND OUTCOMES: Higher Total Protein Concentration In Early Mini-Bal In Ards Predicts Improved Clinical Outcomes
EA201900091A1 (ru) Способ диагностики кандидозного стоматита
Dessein et al. FRI0093 The Framingham Score is a Useful Surrogate Marker of High Risk Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis